Oncology Institute Inc Dossier - Source-backed chat

Oncology Institute Inc

TOINASDAQ

SectorHealth Care

IndustryHealth Care Facilities

Beta (adjusted)0.59

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.13Price as of 3 Aug 2026

Data confidenceNot applicable

Market Cap $512.9M

Enterprise Value $551.7M

Shares Outstanding 109.6M diluted

Moat Rating None

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

The Oncology Institute (TOI) is successfully transitioning from a regional fee-for-service provider to a leading national value-based community oncology platform. By leveraging capitated risk-bearing contracts and a highly productive specialty pharmacy segment, TOI is driving substantial top-line growth while steering toward its first full year of Adjusted EBITDA profitability in 2026. The company's model significantly lowers the total cost of cancer care compared to high-cost hospital systems, creating a strong competitive moat with payors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$8.40

High · most bullish analyst$10.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.3320%

Onboarding of newly delegated lives in Florida faces operational delays or higher-than-expected clinical utilization, depressing patient services gross margins. Specialty pharmacy growth slows down, causing 2026 Adjusted EBITDA to remain slightly negative and delaying the path to self-sustained cash flow.

Base CaseCentral scenario

$7.0050%

TOI delivers on its reaffirmed 2026 guidance, achieving revenue between $630M and $650M and positive Adjusted EBITDA of $0M to $9M. The onboarding of 200,000 Medicare Advantage lives in Florida progresses smoothly, and the company achieves its first full year of positive Adjusted EBITDA and positive free cash flow ($5M to $15M).

Bull CaseUpside scenario

$10.0030%

Rapid maturation of delegated contracts in Florida and accelerated attachment rates in the Specialty Pharmacy segment drive 2026 revenues to the high end of guidance ($650M) and Adjusted EBITDA to exceed $9M. Free cash flow exceeds expectations, allowing self-funded clinic expansion and debt reduction.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong top-line momentum with 41.2% YoY revenue growth in Q1 2026, driven by capitated relationships and record specialty pharmacy fills.
Clear path to near-term profitability, with 2026 projected to be the first full year of positive Adjusted EBITDA ($0M to $9M) and positive Free Cash Flow ($5M to $15M).
Highly differentiated value-based care model that aligns incentives with payors by reducing unnecessary emergency department visits and hospital admissions, as proven by $1.8M in Medicare savings in EOM Performance Period 3.

Key Investment Risks

Operational execution risk associated with onboarding and managing risk for a rapidly growing number of capitated lives, particularly in Florida.
High concentration of revenue in the Specialty Pharmacy segment, which carries lower margins than clinical services and is subject to drug pricing and reimbursement changes.
Dependence on key payor relationships and regional concentration as the platform scales nationally.

Thesis Invalidation Triggers

Failure to achieve positive Adjusted EBITDA for the full year 2026.
Significant deterioration in patient services gross margins due to unmanaged clinical utilization under capitated contracts.
Loss of major payor contracts or failure to successfully onboard the 200,000 Medicare Advantage lives in Florida.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.